NASDAQ:MLTX
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics reported net income of −$227.3M in fiscal 2025. Free cash flow was −$196.0M, and the diluted share count rose 2.5%.Summary generated from MoonLake Immunotherapeutics's SEC filings. Latest annual report filed Feb 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−124.6%
Return on equity−60.5%
Debt / equity0.24
Free cash flow−$196.0M
FCF marginn/a
Share count change+2.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −5 | −65 | −54 | −143 | −245 |
| Net income | −5 | −50 | −36 | −119 | −227 |
| Free cash flow | n/a | −56 | −43 | −117 | −196 |
Recent filings
- 8-KOther events
Sep 30, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 4Insider transaction report
Jul 29, 2026 - 4Insider transaction report
Jul 23, 2026 - 8-KOther events
Jul 15, 2026 - 8-KEntry into a material agreement
Jun 25, 2026 - 8-KRegulation FD disclosure
Jun 22, 2026